Related Experiment Video
Updated: Jul 2, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review
Monika Fischer1, Byron P Vaughn2, Anne F Peery3
1Department of Medicine, University of Indiana, Indianapolis, Indiana.
This expert review provides best practice advice for managing Clostridioides difficile infection (CDI), a common cause of diarrhea. It covers diagnosis, treatment options like fidaxomicin and vancomycin, and strategies for preventing recurrence with microbiota restoration therapies.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Clinical Practice Guidelines
Background:
- Clostridioides difficile infection (CDI) is a significant cause of infectious diarrhea, frequently leading to recurrence and potentially severe or fatal outcomes.
- Effective management strategies are crucial for improving patient outcomes and reducing healthcare burden.
Purpose of the Study:
- To provide best practice advice for the management of Clostridioides difficile infection (CDI).
- To offer timely guidance to clinicians on diagnosis, treatment, and prevention of CDI recurrence.
Main Methods:
- Expert review based on expert opinion and literature review.
- Development of best practice advice statements without formal systematic review or evidence grading.
- Internal and external peer review process.
Main Results:
- Recommends barrier protection and EPA-approved sporicidal agents for CDI prevention.
- Defines CDI diagnosis based on symptoms and laboratory testing, favoring multistep approaches.
- Classifies CDI severity (nonsevere, severe, fulminant) based on clinical and laboratory markers.
- Favors fidaxomicin over vancomycin for nonfulminant CDI due to lower recurrence rates; advises against metronidazole except in fulminant disease.
- Discourages routine test-of-cure; recommends stool testing only for persistent symptoms.
- Suggests tapering vancomycin or fidaxomicin for first recurrence and fecal microbiota-based therapies for subsequent recurrences.
- Considers prolonged, low-dose vancomycin for prophylaxis in specific high-risk patients.
- Recommends multidisciplinary management and high-dose vancomycin for fulminant CDI, with consideration for fecal microbiota transplantation.
- Advises against vancomycin during systemic antibiotic administration for CDI prevention and discourages probiotics.
- Recommends evaluating proton pump inhibitor use during CDI treatment or recurrence prevention.
- Counsels patients with CDI history to avoid unnecessary antibiotics.
Conclusions:
- Best practice advice is provided for CDI management, emphasizing appropriate diagnosis, tiered treatment strategies, and recurrence prevention.
- Fecal microbiota-based therapies are recommended for recurrent CDI, with vancomycin as a suppressive option for select cases.
- Prevention strategies include hygiene, environmental disinfection, and judicious antibiotic use, alongside patient counseling.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Endocarditis III: Medical Management
Acute Pancreatitis II: Clinical Manifestations and Management
